BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) CEO James Passin tells Proactive that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine candidate, demonstrated that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor.
The Vancouver-based biotechnology company said this suggests superior cardiac safety compared to standard coronavirus mRNA and Adenovirus Vector vaccines. The findings show that the company’s vaccine candidate BVX-0320 may not lead to the “unusual but serious myocarditis observed with mRNA vaccines,” said BioVaxys.